Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Interest & Investment Income (2016 - 2025)

Integra Lifesciences Holdings' Interest & Investment Income history spans 17 years, with the latest figure at $4.4 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 10.85% year-over-year to $4.4 million; the TTM value through Dec 2025 reached $18.5 million, down 7.81%, while the annual FY2025 figure was $18.5 million, 7.81% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $4.4 million at Integra Lifesciences Holdings, down from $5.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $5.3 million in Q4 2022 and bottomed at $1.4 million in Q1 2022.
  • The 5-year median for Interest & Investment Income is $4.4 million (2025), against an average of $3.7 million.
  • The largest annual shift saw Interest & Investment Income plummeted 33.78% in 2021 before it surged 269.08% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $1.4 million in 2021, then soared by 269.08% to $5.3 million in 2022, then dropped by 14.35% to $4.5 million in 2023, then increased by 7.56% to $4.9 million in 2024, then fell by 10.85% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Interest & Investment Income are $4.4 million (Q4 2025), $5.0 million (Q3 2025), and $4.7 million (Q2 2025).